PBAC's latest decision on Asunaprevir: Recommended with restriction (2015). Considered for Chronic genotype 1b hepatitis C virus (HCV) infection, administered in combination with daclatasvir, in patients with compensated liver disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Adults (18+ years) with chronic genotype 1b HCV infection (treatment-naïve, treatment-experienced, or ineligible/intolerant to peginterferon) with compensated liver disease.
Therapy area
Hepatology
Line of therapy
Any
Evidence base
Single-arm
Primary endpoint
SVR
Pivotal trial size
969 patients
Key trials
Study 7026, Study 7028
Comparator
no treatment
Economic model
Cost-minimisation
ICER note
ICER not stated in this public summary document; economic evaluation appears incomplete or commercially sensitive details redacted.